Patents Examined by Michael G. Hartley
  • Patent number: 11369700
    Abstract: This invention relates to a Kit formulation to prepare a radioactive, bone-seeking, pharmaceutical drug that has high radiochemical purity (RCP) in a fast, facile and reproducible process. The Kit has at least two vials and a two-part buffer system with instructions on how to make the drug formulation in a radiopharmacy. The drug formulations of this invention can be conveniently and reproducibly prepared with better delivery of the drug to mammals, better radiochemical purity of the formulation for use in treating a mammal having bone pain, one or more calcific tumors or needing bone marrow suppression or bone marrow ablation.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: June 28, 2022
    Assignee: IGL Pharma Inc.
    Inventors: R. Keith Frank, Jaime Simon, Kelli R. Jay
  • Patent number: 11369702
    Abstract: Disclosed herein are kits and methods for preparing radiopharmaceuticals. The kits and methods of the present disclosure can prepare the radiopharmaceuticals without using a heater and computer monitoring equipment. The kit includes a frozen crystal reaction vial, a reagent vial and a labeling holder, wherein the labeling holder contains a heating bag that can heat up to a high temperature of at least 95° C. by adding an aqueous solution.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: June 28, 2022
    Inventors: Ming-Hsin Li, Shih-Wei Lo, Sheng-Nan Lo, Shih-Ying Lee, Su-Jung Chen
  • Patent number: 11369698
    Abstract: The invention provides a novel class of clearable, tumor-targeting and human protein-based MRI nanoprobes and contrast agents and their compositions, and methods of preparation and use thereof.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: June 28, 2022
    Assignee: University of Massachusetts
    Inventors: Gang Han, Yang Zhao
  • Patent number: 11364312
    Abstract: A platinum sulfide protein nanoparticle having near-infrared photothermal effect and multi-modal imaging function, a preparation method therefor and an application thereof. The platinum sulfide nanoparticle having near-infrared photothermal effect and multi-modal imaging function is prepared in aqueous phase by means of formulation screening and process limitation. The nanoparticle has an ultra-small particle size and good stability as well as tumor targeting and photothermal effects and integrates functions of near-infrared imaging, CT imaging, and thermal imaging, so as to achieve high sensitivity, high resolution, and precise positioning of tumors, and to produce high-efficiency photothermal effects under the excitation of near-infrared light to kill tumor cells by thermal ablation, thereby achieving the purpose of efficient, safe, visual, and accurate treatment of tumors. The nanoparticle has the potential for further development and clinical application.
    Type: Grant
    Filed: February 6, 2021
    Date of Patent: June 21, 2022
    Inventors: Hong Yang, Huabing Chen, Xue Wang, Hengte Ke, Ming Li, Tao Xu, Miya Zhang
  • Patent number: 11357873
    Abstract: The present invention relates to the preparation of a series of chiral DOTA, DO3A, DO2A, DO1A, cyclen and their metal complexes, which display properties superior to those of previous DOTA-based compounds, and hence are potentially valuable as a platform for diagnostic applications. The chiral DOTAs reveal a high abundance of twisted square antiprism (TSA) geometry favoring them to be used as potential MRI contrast agents, whereas their rapid labelling properties at mild conditions make them excellent candidates for use as radiometal chelators.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: June 14, 2022
    Inventors: Ga-Lai Law, Lixiong Dai
  • Patent number: 11357874
    Abstract: Methods and compositions for treating, diagnosing and staging cancers, in particular overexpressing the Human Epidermal growth factor Receptor 2 protein (HER2+) given rise to in breast, gastric, gastroesophageal, ovarian, pancreatic cancer and brain tumors, which may be metastatic to the brain or other site. More specifically, the invention provides for Targeted Radionuclide Therapy (TRNT) with a compound of the invention having a peptide that targets the HER2+ cells, a second component for combining metals into complexes through a ring structure (DOTA), and a third radioisotope component, Lu-177 and Ga-68, in which embodiments further include a companion diagnostic, and in which embodiments further include anti-integrin precision medicines for cancers expressing ?v?3 and ?v?5 integrins, HER2+, vascular endothelial growth factor, vitronectin, fibronectin, tenascin, reelin, kindlin and talin.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: June 14, 2022
    Inventor: Stanley Satz
  • Patent number: 11351276
    Abstract: The present disclosure concerns radiopharmaceutical compositions of radioactive halogenated benzylguanidine (such as radioiodinated MIBG) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. In a preferred embodiment, the composition has at least 97% of radiochemical purity for at least 4 days. Advantageously, the compositions of the present disclosure may be devoid of parabens, which are carcinogenic and yet are used in known radioactive MIBG compositions. The present disclosure also provides processes of preparing a radioactive halogenated benzylguanidine composition. The compositions of the present disclosure can be used in diagnosis and treatment of various diseases.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: June 7, 2022
    Assignee: Jubilant Draximage Inc.
    Inventors: Robert William Riddoch, Abmel Xiques Castillo
  • Patent number: 11351275
    Abstract: Provided herein are magnetic resonance imaging (MRI) contrast agents comprising a compound having a structure represented by: Y—X—Z, wherein, X is: Fe(III) or Mn(II), and Y and Z are each independently selected from pyrophosphate and bisphosphonate (e.g., 1-hydroxybisphosphonate), or a pharmaceutically acceptable hydrate and/or salt thereof. Methods of use of the MRI contrast agent are also provided.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: June 7, 2022
    Assignee: Duke University
    Inventor: Christopher David Lascola
  • Patent number: 11344627
    Abstract: Described herein are hybrid nanoparticles that are exosomes loaded with one or more nanoparticle dendrimers. Also included are pharmaceutical compositions including the hybrid nanoparticles and methods of making the hybrid nanoparticles. Also described is a method of treating a human subject by administering to the human subject the above-described hybrid nanoparticles.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: May 31, 2022
    Inventors: Seungpyo Hong, Sin-Jung Park
  • Patent number: 11346798
    Abstract: The present invention relates to a diagnostic device and methods of using the same for diagnostic assays for monitoring the presence of biological samples wherein the device allows for the determination of at least two assay components on one sensor. More specifically, the invention relates to a multi-marker electrochemical impedance spectroscopy sensor comprising a plurality of molecular recognition elements wherein the sensor comprises multiple different molecular recognition element types that are tuned in a manner that alters the frequency of the molecular recognition element type such that it is at a detectably different frequency to the frequency of other molecular recognition element types on the same sensor.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: May 31, 2022
    Inventors: Jeffrey LaBelle, Ugur Demirok
  • Patent number: 11344632
    Abstract: The present invention aims at providing a novel indocyanine compound solving problems of conventionally used indocyanine green, such as solubility in water or physiological saline, a synthesis method and a purification method thereof, and a diagnostic composition including the novel indocyanine compound. Further, provided are a method for evaluating biokinetics of the novel indocyanine compound and a device for measuring biokinetics, and a method and a device for visualizing circulation of fluid such as blood in a living body, which utilize the diagnostic composition. Also, found are a novel indocyanine compound in which a hydrophobic moiety in a near-infrared fluorescent indocyanine molecule is included in a cavity of a cyclic sugar chain cyclodextrin to cover the hydrophobic moiety in the indocyanine molecule with the glucose, and a synthesis method and a purification method thereof.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: May 31, 2022
    Inventors: Katsunori Teranishi, Hitoshi Hirata, Tetsuya Arai
  • Patent number: 11344637
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: May 31, 2022
    Inventors: Celia Dominguez, John Wityak, Jonathan Bard, Christopher John Brown, Michael Edward Prime, Peter David Johnson, Thomas Martin Krulle, Daniel Clark-Frew, Duane Higgins, Matthew Robert Mills, Richard Waldron Marston, Samuel Coe, Samantha Brown, Sarah Hayes
  • Patent number: 11331396
    Abstract: Radiation therapy or radiotherapy (RT) is a powerful treatment where precision and accuracy is crucial. Image Guided Radiotherapy (IGRT) facilitates more accurate position verification, correcting for anatomic changes related to internal organ movement. IGRT thereby helps reduce toxicity of radiotherapy and increases relapse-free survival. An inter-correlation point with a fixed position and volume (a marker) can be applied to indicate the point of treatment clearly in both imaging modalities and to localize and track tumors in real time. In this study, we present the development of a marker based on lactose octaacetate:octapropionate 1:1 containing 3 mM PLA-DTPA(Gd), 40% triglyceride, 5% propylene carbonate and 10% XSAIB (sucrose based CT-contrast agent). The injectable marker had high CT contrast (>1000 HU) and displayed clearly visible, stable T1 contrast enhancement (T1˜900 ms) in the rim over at least 3 weeks with clinically observable resolution.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: May 17, 2022
    Inventors: Thomas Andresen, Rasmus Irming Jølck, Linda Maria Bruun
  • Patent number: 11332482
    Abstract: Au(III) complexes for [18F] trifluoromethylation and methods for producing the same are disclosed. A gold complex comprises Au(CF3)2LR, wherein L comprises a solubility supporting ligand and R comprises an organic substituent. The Au(III) complex can be used to prepare a positron emitting isotope that can be used as tracers for positron emitting tomography (PET) scans.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: May 17, 2022
    Inventors: F. Dean Toste, Mark Daniel Levin, James Patrick O'Neil
  • Patent number: 11330999
    Abstract: The present technology provides 13C- and 15N-labeled probes for imaging one or more mammalian cells using magnetic resonance. Thus, 13C- and 15N-labeled arginine (compound of formula I), xanthine (compounds of formula II and formula III), urea (compounds of formula IV), and glutamine (compounds of formula V), stereoisomers, tautomers, and pharmaceutically acceptable salts thereof are provided. Further methods of making the labelled probes and methods of using the probes to detect arginase, xanthine oxidase, and glutaminase metabolites and activity are provided.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 17, 2022
    Inventors: Andrew Cho, Roozbeh Eskandari, Valentina Di Gialleonardo, Kayvan R. Keshari
  • Patent number: 11324841
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: May 10, 2022
    Inventors: Kwang Yeol Lee, Min Sik Kim, Taek Hoon Kim, Ngoc Phan Vu
  • Patent number: 11324837
    Abstract: Disclosed herein are embodiments of nanoparticle composites that comprise covalently coupled stabilizing agent molecules that improve stability of the nanoparticle composites and allow for tight packing of lipids and/or membranes. The nanoparticle composites can further comprise inhibition inhibitors and/or lipid components that interact to form a hybrid lipid bilayer membrane around the nanoparticle core. The nanoparticle composites can be coupled to drugs, targeting moieties, and imaging moieties. The nanoparticle composites can be used for in vivo drug deliver, disease diagnosis/treatment, and imaging.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: May 10, 2022
    Assignee: Portland State University
    Inventor: Marilyn Mackiewicz
  • Patent number: 11318216
    Abstract: Provided is a method for producing a radiohalogen-labeled compound, the method comprises: a step in which a radiohalogen-labeling precursor compound (S-L) having a leaving group (L) capable of being nucleophilically substituted by a radioactive halide ion (X?) is subjected to a radiohalogenation reaction to obtain a reaction mixture RM1 which contains the radiohalogen-labeling precursor compound (S-L) and a reaction product (S—X) resulting from the radiohalogenation reaction; a step in which the reaction mixture RM1 is mixed with a polyvalent acid or a salt thereof to obtain a reaction mixture RM2; and a step in which the reaction product (S—X) is purified from the reaction mixture RM2 by a solid phase extraction method.
    Type: Grant
    Filed: May 28, 2018
    Date of Patent: May 3, 2022
    Inventors: Yuki Okumura, Daisaku Nakamura, Masato Kiriu, Hiroaki Ichikawa, Gota Tonoya, Naomi Sugimoto
  • Patent number: 11318105
    Abstract: A method for preparing albumin nanoparticles based on free radical oxidation, comprising the following steps: preparing albumin aqueous solution with an albumin concentration of 1-20 mg/mL; (2) whilst stirring, adding free radical generating agent to the albumin aqueous solution, and continuing to stir and react for 1-60 min at 15-50° C.; the free radicals generated by the free radical generating agent are used for oxidizing the albumin, and the oxidized albumin molecules assemble to form albumin nanoparticles that are mainly bonded by hydrophobic action, thereby obtaining an albumin nanoparticle suspension. The present invention implements improvement by means of the key reaction mechanism of the nanoparticle preparation method and the corresponding design of the finishing process and, compared to the prior art, can effectively solve the problems of the complexity, high cost, and high toxicity of preparing nanoparticles.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: May 3, 2022
    Inventors: Jiangling Wan, Han Luo, Jianyong Sheng, Xiangliang Yang
  • Patent number: 11319313
    Abstract: Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: May 3, 2022
    Assignee: Poxel SA
    Inventors: Laure Françoise Valérie Navarre, Emeline Gardette, Sébastien Bolze, Sheila DeWitt, Vincent Jacques